Drug Interaction Study Between Dorzagliatin and Empagliflozin

Inclusion Criteria: 1. Subjects diagnosed with T2DM within at least 3 months prior to screening 2. Male and/or female subjects between the ages of 30 and 65 years, inclusive; 3. Body Mass Index (BMI) of 19 to 38 kg/m2, inclusive, at screening; 4. Fasting C-peptide test result \>0.3 nmol/L (\>0.90 ng/mL); 5. HbA1c ≥7% and ≤10.5%; Exclusion Criteria: 1. Fasting blood glucose at screening or Day -1 ≤110 or ≥270 mg/dL ; 2. Type 1 diabetes mellitus; 3. Reported incidence of severe hypoglycemia within 3 months prior to screening; 4. Known contraindications to empagliflozin; 5. Clinically significant gastrointestinal disorder; 6. History or symptoms of clinically significant cardiovascular disease; 7. History of more than three urinary tract infections and/or more than three genital fungal infections in the last 12 months; 8. Reported history of clinically significant central nervous system disease including within one year prior to screening; 9. Reported history of liver disease; 10. Reported history of clinically significant renal disease; 11. Estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73m2; 12. Acute or chronic metabolic acidosis, including diabetic ketoacidosis; 13. Known or suspected malignancy; 14. Any reported hypersensitivity or intolerance to empagliflozin; 15. Antidiabetic treatment with insulin, sulfonylureas, thiazolidinediones or GLP-1 agonist within 3 months prior to screening; 16. Systolic blood pressure \<90 or \>160 mmHg or diastolic blood pressure \<60 or \>100 mmHg at screening; 17. A hospital admission or major surgery within 90 days prior to screening; 18. Uncontrolled hypertriglyceridemia \>500 mg/dL; 19. Positive blood screen for HIV, HBsAg, or hepatitis C antibody; 20. Positive pregnancy test result; 21. Treated with any investigational drugs within 6 weeks prior to screening; 22. Reported history of prescription drug abuse; 23. Reported history of alcohol abuse 24. Reported history of donation or acute loss of blood during the 90 days prior to screening;